Denali Therapeutics (NASDAQ:DNLI) is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Region: North America
Precision Biosciences
Precision Biosciences (NASDAQ:DTIL) is developing a gene-editing platform based on their proprietary ARCUS nuclease for multiple applications with a focus on human therapeutics.
Quartet Health
Quartet Health is developing care coordination software and services designed to improve clinical outcomes and reduce the cost of care for patients where behavioral health is the primary or a comorbid condition. Quartet Health was acquired by NeuroFlow in 2025.
Caribou Biosciences
Caribou (NASDAQ: CRBU) is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. Caribou’s proprietary technologies put the company at the forefront of the development of new medical therapies.
Semma Therapeutics
Semma Therapeutics is a regenerative medicine company founded to develop transformative stem cell-derived therapies to provide a functional cure for patients with diabetes. This company was acquired by Vertex in 2019.
Stride Health
Stride Health is an early-stage healthcare IT company developing a multi-carrier, private health insurance marketplace for the individual segment.
TraceLink
TraceLink the world’s largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes.
Avidity Biosciences
Avidity Biosciences is a biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASC™) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics to overcome barriers to the delivery of siRNA and target genetic drivers of disease. Avidity Biosciences, (formerly NASDAQ: RNA/RNAM) is no longer a publicly traded company. Novartis acquired Avidity.
Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47. Surface Oncology went public in 2018 (NASDAQ: SURF). The company has since been acquired by Coherus BioSciences and is no longer a publicly traded company. Surface Oncology was acquired in 2023.
Cogent Biosciences
Cogent Biosciences (NASDAQ:COGT) (formerly Unum Therapeutics) is developing precision therapies for genetically defined diseases with a clinical stage therapy for systemic mastocytosis.